The J-curve phenomenon revisited

Blood Pressure

Volumn 18, Issue 4, 2009, Pages 168-170

  Hedner, Thomas ^a   Oparil, Suzanne ^a   Narkiewicz, Krzysztof ^a   Kjeldsen, Sverre E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN;

ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; EDITORIAL; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HIGH RISK POPULATION; HYPERTENSION; HYPOTENSION; MORTALITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION;

EID: 70849108141     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037050903145386     Document Type: Editorial

References (18)

1. Cruickshank J. The J-curve in hypertension. Current Cardiology Reports. 2003; 5: 441-452 .
2. Onrot J. Hypertension and the J-curve. How far should we go? Can Fam Physician. 1993; 39: 1939-1943 .
3. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA. 1991; 265: 489-495 .
4. Cruickshank J, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987; 329: 581-584 .
5. Samuelsson OG, Wilhelmsen LW, Pennert KM, Wedel H, Berglund GL. The J-shaped relationship between coronary heart disease and achieved blood pressure level in treated hypertension: further analysis of 12 years of follow-up of treated hypertensives in the Primary Prevention Trial in Gothenburg, Sweden. JHypertens. 1990; 8: 547-555 .
6. D'Agostino RB, Belanger AG, Kannel WB, Cruickshank JM. Relation of low diastolic pressure to coronary heart disease death in presence of myocardial infarction: The Framingham study. BMJ. 1991; 303: 385-389 .
7. MacMahon S, Peto R, Cutler J, Collins C, Sorlie P, Neaton J, et al. Blood pressure, stroke and coronary heart disease. Part 1: Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990; 335: 765-774 .
8. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351: 1755-1762 . (Pubitemid 28269185)
9. Hansson L. Antihypertensive treatment: does the J-curve exist? Cardiovasc Drugs and Ther. 2000; 14: 367-372 .
10. Cruickshank J. Antihypertensive treatment and the J-curve. Cardiovasc Drugs and Ther. 2000; 14: 373-380 .
11. Kannel WB, Wilson PW, Nam BH, D'Agostino RB, Li J. Alikely explanation for the J-curve of blood pressure cardiovascular risk. Am JCardiol. 2004; 94: 380-384 .
12. Marschner IC, Simes RJ, Keech A. Biases in the identification of risk factor thresholds and J-curves. Am JEpidemiol. 2007; 166: 824-831 .
13. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. Acalcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003; 290: 2805-2816 .
14. Messerli FH, Mancia G, Conti CR, Hewkin AC, kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006; 144: 884-893 .
15. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T, Yusuf S. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. JHypertens. 2009; 27: 1360-1369 .
16. Zanchetti A, Mancia G, Black HR, Oparil S, Waeber B, Schmieder RE, Bakris GL, Messerli FH, Kjeldsen SE, Ruilope LM. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. JHypertens. 2009; 27: 673-679 .
17. Julius S, kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUErandomised trial. Lancet. 2004; 363: 2022-2031 .
18. Messerli FH, Mancia G, Weber 18. MA, Kjeldsen SE, Holzhauer B, Hua TA, Zappe D, Julius S. Low Blood Pressure is Associated with Increased Cardiovascular Morbidity (J-shaped Curve) in Treated Hypertensive Patients with Increased Cardiovascular Risk: The VALUERandomized Trial. JAm Coll Cardiol. 2009; 53 ( Suppl. A): A46.